Pictured: Roche’s constructing in France/iStock, HJBC
Roche on Thursday introduced that it’ll cease the Section II/III SKYSCRAPER-06 examine following disappointing information from its investigational anti-TIGIT antibody tiragolumab, which was unable to considerably enhance survival in sufferers with non-small cell lung most cancers.
The pivotal examine, which enrolled 524 sufferers with non-squamous non-small cell lung most cancers (NSCLC), examined an investigational routine combining tiragolumab with Roche’s PD-L1 blocker Tecentriq (atezolizumab) within the first-line setting. For the management, the pharma used a mix of Merck’s Keytruda (pembrolizumab) and chemotherapy.
On the time of the first evaluation, the tiragolumab routine confirmed “diminished efficacy” in progression-free survival (PFS) with a hazard ratio of 1.27 in favor of the Keytruda arm. Total survival (OS) information, which weren’t mature on the time of the evaluation, additionally leaned in favor of Merck’s blockbuster with a hazard ratio of 1.33.
When it comes to security, SKYSCRAPER-06 discovered no new indicators of concern with hostile occasions per what had beforehand been established for tiragolumab and Tecentriq.
Roche CMO Levi Garraway in a press release stated that the corporate discovered the outcomes “disappointing,” including that “it was our hope that this mixture may yield improved outcomes” in metastatic non-squamous NSCLC. The pharma will coordinate the examine’s termination with its investigators and can current full findings and analyses from the examine at an upcoming medical congress.
Tiragolumab is an investigational antibody that works by focusing on TIGIT, an immune receptor discovered on sure immune cells, which most cancers cells can exploit to weaken the physique’s anti-cancer exercise. Tiragolumab’s mechanism of motion permits it to as a substitute amplify the immune response and acts in a complementary method to the favored PD-L1 blockers.
Roche is additionally finding out tiragolumab in small cell lung most cancers, cervical most cancers, esophageal most cancers, head and neck most cancers and different heme and strong tumors. In January 2024, the pharma reported that tiragolumab plus Tecentriq and chemotherapy led to a big enchancment in PFS in sufferers with esophageal squamous cell carcinoma, in contrast with chemo alone.
The mixture remedy additionally improved OS, Roche stated on the time.
Based mostly on the readout from SKYSCRAPER-06, Roche will assess if it must make any adjustments to its different medical improvement applications.
In April 2024, Roche gained the FDA’s approval to make use of Alecensa (alectinib) for the adjuvant remedy of early-stage NSCLC optimistic for ALK mutations. The drug is the first-ever ALK inhibitor to be authorised for this indication.
Tristan Manalac is an impartial science author based mostly in Metro Manila, Philippines. Attain out to him on LinkedIn or electronic mail him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.